Mode
Text Size
Log in / Sign up
N/A N=42 Randomized Single-blind Prevention

Intraoperative Warming Comparison of Devices

Hypothermia

Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcome: Primary: Percent of Patients With an Average Intraoperative Temperature Greater Than or Equal to 36 Celcius — 56; 90 percentage of participants — p=0.027

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Dynatherm Medical vitalHEAT Temperature Management System vH2 (Device); Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of South Florida
Primary completion
Jul 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent of Patients With an Average Intraoperative Temperature Greater Than or Equal to 36 Celcius
56; 90 0.027 sig
PRIMARY
Percent of Subjects With an Initial PACU Sublingual Temperature of ≥ 36º C.
95; 100 1.0
PRIMARY
Percentage of Patients With a Post Operative Sublingual Temperature Above 36 Degrees Celcius
95; 100
SECONDARY
Comparison of the Core Body Temperatures at 60 Minutes Post Anesthesia Induction,as Assessed by Esophageal Probe.
36.4; 36.1 0.078
SECONDARY
Average Intraoperative Esophageal Temperature
36.3; 36.0
SECONDARY
Median Post Anesthesia Care Unit Sublingual Temperature
36.4; 36.6

Summary

Hypothermia is a common and serious complication during anesthesia and surgery. Anesthetic-induced hypothermia results from the inhibition of thermoregulatory control and exposure to cold operating room environment. Various warming methods, such as warm blankets, forced-air warmers and circulating water mattresses, are currently used to prevent and treat mild perioperative hypothermia. All are cutaneous approaches that rely on heating the peripheral tissues in order to increase the thermal core temperature. Application of cutaneous warming system blankets/pads are limited by location/extent of operative site; for example, in certain procedures such as laparatomies, reconstructive plastic surgery or orthopedic surgery, only a limited amount of skin surface is available for warming application. The Dynatherm vitalHEAT technology takes advantage of the body's natural thermoregulatory system to channel thermal energy to the body's core non-invasively at a rapid rate. The vital heat (vH2) system is designed to treat hypothermia during the peri-operative period through a combination of localized heat and vacuum application to one hand & forearm; this application 1) opens the arteriovenous anastamoses located in the palm of the hand and 2) conductively warms the extremity thus effectively warming the blood flow to the body's core. The vital heat vH2 system is a portable and compact warming device which provides a non-invasive approach to warming patients during surgery. The primary objective of this study is to determine if the Dynatherm Medical vitalHEAT (vH2) Temperature Management System is as effective as the forced-air warming Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN) for maintenance of intraoperative body temperature in patients undergoing abdominal surgery under general anesthesia. The critical endpoints to be evaluated in making this determination are 1) % of subjects with an average intraoperative esophageal temperature of ≥ 36º C and 2) % of subjects with an initial post anesthesia care unit sublingual temperature of ≥ 36º C. Secondary objectives include 1) comparison of the core body temperatures @ 60 minutes post anesthesia induction, 2) comparison of temperature trends during surgery and 3) comparison of the subjects' post anesthesia care unit temperature trends and hypothermic symptoms such as shivering.

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing elective open abdominal surgical procedures with an expected duration of 2 to 4 hours and requiring general anesthesia
  • American Society of Anesthesiologists(ASA) physical status I-III
  • Patient age: > 18 years and 80 years
  • Patients with break in skin integrity on the extremity selected as the application site
  • Patients with history of upper extremity peripheral vascular disease
  • Patients with history of allergic skin conditions of the upper extremities
  • Patients with history of bleeding disorders/coagulopathy
  • Patient with history of malignant hyperthermia
  • Patients who are pregnant
  • Patient unwilling or unable to give informed consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00650260). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search